Ciência e terapia do câncer

Management of Hodgkin’s Disease, Ino Experience 2014-2016

Abstract

Mosse B. A. Wilfried*, Kietga Georges Gaël, Messouna Mohamed, Compaoré Bertrand, Seka Evrard Narcisse, Patricia Agbanglanon, Halima Ahmut, Bouhia Hasnae, Elmajjaoui Sana and Noureddine Benjaafar

Over the past century, Hodgkin's Lymphoma (HL) has gone from a uniformly fatal disease to a curable disease in approximately 75% of patients worldwide. The selection of therapy should balance the desire to maintain a high rate of cure with the need to minimize long-term complications. In this retrospective study, we propose to report the experience of the management of this pathology to the National Institute of Oncology (INO) in Rabat. We recorded and collected data from 152 patients admitted to the National Institute of Oncology for MDH, the average age is 36.2 +/-16.3 years with extremes of 17 and 81 years. Men made up 52%?? of the total population. The favourable localized stages (IA, IIA) represented 20.4%, we did not have enough data to classify 7 patients. ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) was the 1st line protocol in 66% of patients, BEACOPP standard 13.4% (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone); some have BEACOPPP had the switcher protocol to the BEACOPP standard after 3 cures). 55.9% of patients received between 3 and 6 courses, 17.8% between 7 and 8 courses.

27.2% of patients had curative adjuvant radiotherapy using the irradiation technique (IFRT) Field concerned Radiotherapy with doses of 20 Gy and 30 Gy depending on the response to the initial medical treatment and the initial stage. The median overall survival for all stages was 72.9% after 84 months of follow-up. All-stage event-free survival was 69.3%. The over hall survival according to the favourable localized stages (IA and IIA) was 75.1% higher than that of the unfavourable stages of 71.5% (p=0.186). Patients who had adjuvant radio therapy had overall survival (72.4%) and those who had not been irradiated 72.1% (p=0.733). All-stage event-free survival was 65.1% after 84 months follow-up 95% CI (62.2%-67.9%). Hodgkin lymphoma is a curable malignant tumor in the early and late stages. The treatment should be refined on prognostic models.